ADCTA immunotherapy
/ Safe Save Cell
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 20, 2020
Autologous Dendritic Cell / Tumor Antigen (ADCTA) for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM)
(clinicaltrials.gov)
- P3; N=118; Recruiting; Sponsor: Safe Save Medical Cell Sciences & Technology Co.,Ltd.
New P3 trial
1 to 1
Of
1
Go to page
1